Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

970 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Toward Precision Medicine: Development and Validation of A Machine Learning Based Decision Support System for Optimal Sequencing in Castration-Resistant Prostate Cancer.
Lim H, Yoo JW, Lee KS, Lee YH, Baek S, Lee S, Kang H, Choi YD, Ham WS, Lee SH, Chung BH, Halawani A, Ahn JH, Koo KC. Lim H, et al. Among authors: chung bh. Clin Genitourin Cancer. 2023 Aug;21(4):e211-e218.e4. doi: 10.1016/j.clgc.2023.03.012. Epub 2023 Mar 30. Clin Genitourin Cancer. 2023. PMID: 37076338
Letter to the editor.
Chung BH. Chung BH. Prostate Int. 2013;1(1):2. doi: 10.12954/PI.13002. Prostate Int. 2013. PMID: 24223394 Free PMC article. No abstract available.
Patients' self-management of adverse events and patient-reported outcomes in advanced renal cell carcinoma treated with targeted therapies: A prospective, longitudinal, observational study.
Hong SH, Chung HS, Seo IY, Kwon TG, Jeong H, Chung JI, Jeon SH, Park JY, Ha HK, Chung BH, Song W, Kim YJ, Kim SH, Lee JS, Lee J, Chung J. Hong SH, et al. Among authors: chung hs, chung ji, chung j, chung bh. J Patient Rep Outcomes. 2022 Dec 16;6(1):125. doi: 10.1186/s41687-022-00532-0. J Patient Rep Outcomes. 2022. PMID: 36525150 Free PMC article.
Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.
Chowdhury S, Bjartell A, Agarwal N, Chung BH, Given RW, Pereira de Santana Gomes AJ, Merseburger AS, Özgüroğlu M, Juárez Soto Á, Uemura H, Ye D, Brookman-May SD, Londhe A, Bhaumik A, Mundle SD, Larsen JS, McCarthy SA, Chi KN. Chowdhury S, et al. Among authors: chung bh. Ann Oncol. 2023 May;34(5):477-485. doi: 10.1016/j.annonc.2023.02.009. Epub 2023 Feb 27. Ann Oncol. 2023. PMID: 36858151 Free article. Clinical Trial.
970 results